Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Avoid Slam: Exploring the Pickup Truck Transformation - 2A Sweet Choice: Pick Your #1 Cake!
- 3One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- 4Top 15 Style Creators Changing the Business
- 5The Best Portable Applications for Psychological wellness and Prosperity
- Forum Dvorah demands clear support for women in combat as IDF gender debate escalates
- Step by step instructions to Involve Compact disc Rates for Magnanimous Giving
- Rediscovering Imagination in Adulthood: Individual Creative Excursions
- Gauging the Upsides and downsides of Visas: A Complete Aide
- 15 Outrageous Cosplay Outfits That Will Blow You Away
- Manual for Picking Coastline Travel
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- See a half-lit moon shine among the stars of Aquarius on Nov. 27
- A NASA spacecraft orbiting Mars may be dead
